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Abstract: Diabetes is a chronic disorder, which manifests when insulin levels or resistance to 
insulin action becomes insufficient to control systemic glucose levels. Although the number of 
available agents to manage diabetes continues to expand rapidly, the maintenance of euglycemia 
by individuals with diabetes remains a substantial challenge. Unfortunately, many patients with 
type 1 and type 2 diabetes will ultimately experience diabetes complications. These complica-
tions result from the toxic effects of chronic hyperglycemia combined with other metabolic 
derangements that afflict persons with diabetes. This review will present a comprehensive look 
at the complications of diabetes, the risk factors for their progression, the mechanistic basis 
for their development, and the clinical approach to screening for, preventing, and treating these 
sequelae. In addition, since diabetes is commonly diagnosed in childhood, we will provide a 
special focus on the care of the adolescent patient.
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Introduction
Diabetes describes a collection of chronic disorders in which insulin production is 
insufficient to maintain normal glucose homeostasis. Whether insulin insufficiency 
is due to loss of pancreatic islet beta cells or resistance to insulin action, the end 
result is chronic elevation of systemic glucose levels. Trials such as the Diabetes 
Control and Complications Trial (for type 1 diabetes)1 or the UK Prospective 
Diabetes Study (for type 2 diabetes)2 have demonstrated the benefits of intensive 
management on long-term disease complications. However, the implementation 
of intensive management strategies has remained a challenge particularly with the 
increasing number of patients with diabetes worldwide, and many patients struggle 
to maintain euglycemia. In addition, emerging evidence suggests that in some 
circumstances, intensive glucose control alone may be insufficient to completely 
prevent the complications associated with diabetes.
For type 1 diabetes (T1DM), there is likely to be a window between initial 
diagnosis and the onset of diabetes complications. The case is more challenging in 
the setting of type 2 diabetes (T2DM) where organ damage may exist at the time 
of initial presentation. While there are methods to manage diabetes complications, 
these complications are generally progressive and often become irreversible; thus, 
mitigating the risk for their appearance and identifying and treating them early is of 
utmost importance for clinicians and patients. While T1DM remains the predominant Vascular Health and Risk Management 2009:5 1016
Moore et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
diagnosis in childhood, the number of cases of T2DM 
continues to rise, and thus anticipation and intervention 
for all forms of diabetes is becoming a primary role of the 
pediatric endocrine provider. In this review, we will address 
1) the risk factors that predict micro- and macro-vascular 
complications, 2) the basic mechanisms by which these risk 
factors are translated into tissue injury, and 3) how clinical 
and scientific data can be used to direct a rational approach 
to therapeutic interventions. Throughout, we will provide an 
additional focus on the pediatric patient and consider how 
best to set the stage in childhood to empower patients to 
prevent complications throughout their lives.
Clinical overview of vascular 
disease in diabetes
It has long been appreciated that persons with diabetes are at 
substantial risk for tissue injury in organs supplied by an end-
arterial system due to microangiopathy. These microvascular 
complications, which include nephropathy, retinopathy, and 
neuropathy, have even served as end-points in numerous large 
studies of diabetes control and its benefits. As the manage-
ment of diabetes and these complications has improved, it has 
become more apparent that there are additional factors that 
limit the quality and length of life of patients with diabetes. 
Indeed, there is substantial emerging evidence that these 
patients are also at risk for macrovascular disease including 
heart disease and stroke. In this section we will consider the 
epidemiology of these complications and the clinical risk 
factors that may predict their progression.
Epidemiology of vascular disease 
in patients with diabetes
In the pediatric population, T1DM has historically been more 
prevalent than T2DM, with an incidence of approximately 
24 per 100,000 people. T2DM is becoming more common in 
concert with increasing rates of childhood obesity. Incidence 
rates of T2DM have been reported between 17 and 49 per 
100,000, with most new pediatric diagnoses documented 
among 15- to 19-year-old minority groups.3 The eventual 
metabolic and vascular consequences of T1DM and T2DM 
are essentially the same. The microvascular complications 
associated with diabetes mellitus, which include nephropathy, 
retinopathy, and neuropathy, lead to the sequelae commonly 
associated with diabetes such as renal failure, blindness, 
and distal extremity amputations. These complications 
greatly affect the quality of life for patients with diabetes, 
and they also contribute to a decreased life expectancy by an 
average of 5 to 10 years.4 In the following sections, we will 
review the clinical presentation of the range of vascular 
complications of diabetes.
Nephropathy
Diabetic nephropathy is a condition that can lead to end 
stage renal disease requiring dialysis and eventual transplant. 
Patients may initially develop microalbuminuria that can 
develop into gross proteinuria. Gross proteinuria is an indica-
tion of widespread microvascular disease. These patients also 
develop elevated blood pressures and decreased glomerular 
filtration, eventually leading to renal failure. In the past, 
diabetic nephropathy has been reported to develop in about 
40% of patients with T1DM and about 20% of patients 
with T2DM.5 With improved diabetes care, the incidence of 
reported diabetic nephropathy is now about 15% to 20% in 
T1DM and T2DM. In adults with T1DM, clinical findings 
of diabetic nephropathy (microalbuminuria) can appear as 
early as 5 years after onset, which can eventually lead to gross 
proteinuria after an average of about 17 years of disease.5 
End stage renal disease develops after an average of about 
23 years of  T1DM.5 The timeline is more difficult to quantify 
in T2DM, as onset of disease may be uncertain. The risk 
of developing nephropathy in T1DM decreases after about 
25 years if a patient has not developed gross proteinuria. 
In pediatrics, microalbuminuria can be seen shortly after 
disease onset in 25% to 50% of patients. This initial micro-
albuminuria is usually reversible with insulin administration 
and is not associated with histological lesions of the filtration 
system. Progression to overt proteinuria is rare in childhood 
and is seen in just 1% to 1.5% of pediatric patients.6 After 
about 5 years, as in the adult population, susceptible patients 
will develop more concerning microalbuminuria associated 
with changes of the filtration system such as glomerular 
basement membrane thickening and mesangial expansion.6 
About 7 to 10 years after diagnosis, one-third of patients 
will develop microalbuminuria. One-fifth will develop gross 
proteinuria, which will progress to end stage renal disease 
after 5 to 10 years.6
Retinopathy
Retinopathy is the result of macrovascular occlusion and 
microvascular leakage into the retina. Diabetic retinopathy 
is a vision-threatening process that leads to almost 10,000 
new cases of blindness in the US each year. It is the leading 
cause of blindness between the ages of 25 to 74 years, 
and is responsible for about 12% of blindness in the US.7 
It is reported in the T1DM population that children have Vascular Health and Risk Management 2009:5 1017
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a negligible risk of developing retinopathy during the first 
decade of life, even when diagnosed prior to age two years.8 
In adults after seven years of T1DM, about 50% of patients 
have some degree of retinopathy; while after twenty years, 
approximately 90% demonstrate retinopathy.7
Neuropathy
Diabetic neuropathy is the result of slowed motor and 
sensory nerve conduction that most commonly develops 
between 5 and 10 years after onset of disease.4 Neuropathy 
can present as peripheral sensorimotor, cranial, peripheral 
motor, and autonomic neuropathy. The peripheral senso-
rimotor neuropathy is symmetric and mostly affects the feet, 
leading to diminished sensation and paresthesia. Diminished 
sensation can cause altered perception of foot pressures and 
altered foot architecture. This change can result in injury, 
non-healing wounds, and eventual amputations. Alternatively, 
diabetic neuropathy can lead to painful and debilitating hyper-
sensation and burning dysesthesias, which makes ambulation 
difficult.4 The prevalence of peripheral neuropathy in the 
pediatric population has been reported to range between 7% 
to 57% depending on the diagnostic criteria used, with sub-
clinical neuropathy reported to occur in 57% of children and 
adolescents with T1DM.9 On average, about 50% of patients 
with diabetes will develop neuropathy.9 As prevalence is 
based on disease duration, the majority of affected patients 
will be those who were diagnosed in childhood.
Macrovascular disease
While microvascular disease contributes significantly 
to morbidity as well as to mortality in patients with 
diabetes, macrovascular complications are likely to be 
equally important determinants of life-span and quality 
of life. Macrovascular complications include coronary 
artery disease, stroke, and peripheral vascular disease. 
By the 1970s and 1980s, atherosclerotic disease had 
been recognized as one of the foremost complications of 
diabetes.10–13 While over the past 30 years the majority of 
studies of macrovascular disease have focused on the T2DM 
population, more recent studies specifically examining the 
T1DM population are now available. The Diabetes UK 
Cohort Study14 followed a cohort of over 23,000 patients 
with T1DM for an average of 17 years per subject. This 
study demonstrated statistically significant higher stan-
dardized mortality ratios (SMR, ie, the ratio of observed 
deaths to expected deaths in a standard population) from 
heart disease across all age groups and genders for patients 
with T1DM compared with the corresponding general 
population.14 Across all age groups in the study, men with 
T1DM carried a SMR of 4.5 for ischemic heart disease 
while women with T1DM had a SMR of 8.8. These data 
also showed higher incidence of cardiovascular mortality in 
younger adults with T1DM, particularly a staggeringly high 
SMR for women with T1DM under age 39. Women had an 
SMR of 44.8 in the 3rd decade of life and 41.6 in the 4th 
decade, indicating a loss of cardioprotection seen in young 
women without diabetes. Increased mortality rates across 
age groups from stroke were similarly observed.10
In addition to having higher morbidity and mortality from 
macrovascular disease, patients with T1DM are thought to 
have atherosclerotic changes at an earlier age. Studies by 
Jarvisalo et al and Krantz et al evaluated carotid intima media 
thickness (IMT), a sensitive marker for coronary and cerebral 
vascular disease, in children, adolescents, and young adults 
with T1DM.15–18 Carotid IMT was found to be significantly 
greater in patients with T1DM than their age-matched, 
unaffected counterparts.
Risk factors for the development 
of vascular complications
The complications of diabetes are numerous and ultimately 
affect a large proportion of patients with the disease. Efforts 
to prevent these complications are aided by numerous studies 
that have uncovered contributing risk factors to the suscepti-
bility to, and progression of, organ damage. The preponder-
ance of evidence suggests a highly influential role of blood 
glucose levels in modifying the risk for these processes, 
particularly the vascular complications. In addition, there 
are several additional, modifiable parameters unrelated to 
glycemic control that may play key roles in the development 
of vascular complications.
Role of glycemic factors: hyperglycemia 
as the culprit
Hyperglycemia plays an important role in the microvascular 
and macrovascular complications of diabetes. The Diabetes 
Control and Complications Trial (DCCT), which studied 
patients with T1DM, demonstrated a significant reduction 
of microvascular complications from diabetes through the 
reduction of participants’ glycosylated hemoglobin (HbA1c). 
Lowering HbA1c from 8.0% to 7.2% reduced microvascular 
complications by as much as 34% to 76%.1 The United King-
dom Prospective Diabetes Study (UKPDS), which examined 
patients with T2DM, also helped to demonstrate the benefits 
of intensive blood-glucose control by showing that a reduction Vascular Health and Risk Management 2009:5 1018
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of  HbA1c levels by 1% could decrease microvascular 
complications of diabetes by approximately 25%.2
The DCCT also demonstrated that glycemic control 
could also reduce the risk of diabetic nephropathy in 
pediatric patients. In the DCCT, patients were divided into 
two groups treated either with intensive insulin therapy or 
conventional therapy to determine whether intensive therapy 
could delay the development of complications. To ascertain 
whether intensive therapy could slow the progress of pre-
existing complications, patients were further subdivided 
into a primary prevention cohort, who had no complications 
at baseline, and a secondary intervention cohort, who had 
some evidence of complications at baseline. These patients 
had mild to moderate retinopathy and urine albumin excre-
tion under 200 mg per 24 hours. In the adolescent subgroup 
of the DCCT, which included patients aged 13 to 17 years, 
there was a 10% risk reduction in the development of 
microalbuminuria in the group that received intensive insu-
lin management as compared to the conventionally treated 
group in the primary prevention cohort. In the secondary 
intervention cohort, the risk of developing microalbuminuria 
was decreased by 55% in the group that underwent intensive 
insulin management as compared to the conventionally 
treated group.6 In the full evaluation of all patients age 13 
to 29, the risk of nephropathy was decreased by 35% in the 
primary prevention cohort and 45% in the secondary inter-
vention cohort (Figure 1).19
Optimizing glycemic control of pediatric patients was 
also shown to improve outcomes of retinopathy in the 
DCCT.1 In the adolescent group age 13 to 17 years old, the 
patients in the aggressive glucose management group had 
a 53% decrease in risk of initially developing retinopathy 
(in the primary prevention cohort). The risk of progression 
of retinopathy was decreased by 70% in the secondary 
intervention cohort.1,20 In those patients 13 to 29 years old, 
the risk of retinopathy was decreased by 75% in the primary 
prevention cohort and 55% in the secondary intervention 
cohort.19
The DCCT further demonstrated positive effects of 
intensive insulin therapy on the prevention of diabetic 
neuropathy1. Rigorous metabolic control decreased the 
prevalence of symptomatic, electrophysiologic, and 
autonomic indicators of neuropathy by 38% to 59%. After 
5 years of treatment with intensive insulin therapy, evidence 
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Figure 1  The Diabetes Control and Complications   Trial: percent reduction of microvascular complication with intensive therapy.  Patients age 13 to 39 with T1DM were 
divided into two cohorts, primary prevention cohort (no complications), and secondary intervention cohort (mild to moderate retinopathy, urine microalbumin 200 mg/24 h). 
The patients who underwent intensive therapy with insulin showed significant reduction of microvascular complications in both cohorts.
Drawn from data of Skyler JS. Diabetic complications.  The importance of glucose control. Endocrinol Metab Clin North  Am. 1996;25(2):243–254.19Vascular Health and Risk Management 2009:5 1019
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of neuropathy was reduced by 50%. In the primary pre-
vention cohort, only 3% of patients treated with intensive 
therapy versus 10% of patients treated with conventional 
therapy showed signs of diabetic neuropathy. In the second-
ary cohort, evidence of clinical neuropathy was seen in only 
7% of patients treated with intensive therapy versus 16% 
of patients treated with conventional therapy.9 Overall, the 
neuropathy was decreased by 70% in the primary preven-
tion cohort and 55% in the secondary intervention cohort.19 
Specific data restricted to the pediatric population have not 
been available.
There is also strong data from UKPDS on glycemic 
control in preventing microvascular complications in patients 
with T2DM.2 The combined risk of vitreous hemorrhage, 
need for photocoagulation and renal failure was decreased 
by 25% by reducing HbA1c from 7.9% to 7.0%. As the 
patients enrolled in the UKPDS study were between the 
ages of 25 and 65, there are no specific data from the study 
about glycemic control in pediatric patients with T2DM, 
although the importance of proper glycemic control is 
strongly suggested by the available adult data.
The observational Epidemiology of Diabetes Interventions 
and Complications (EDIC) study provides additional 
evidence that indicates intensive therapy has long-term 
benefits in preventing macrovascular disease in T1DM 
patients. Of the 1441 patients aged 13 to 40 who had been 
randomly assigned to intensive or conventional insulin 
therapy during a mean of 6.5 years in the DCCT study, 97% 
enrolled in the EDIC at the completion of the DCCT study 
in 1993. The conventional treatment group was offered 
intensive treatment and the difference in mean HbA1c, 
which was initially 7.4% in the intensive treatment group 
and 9.1% in the conventional group, narrowed at the end 
of the 11-year follow up to a non-significant difference of 
7.9% and 7.8% in the intensive and conventional treatment 
groups, respectively.
A report from EDIC showed a relationship between 
glycemia and carotid artery IMT. At year 1 of EDIC, carotid 
IMT was similar to the age and sex-matched non-diabetic 
population, but at year 6 the thickness was significantly greater 
in the patients with diabetes compared with the controls. 
Additionally, after adjustment for sex, age, instrumentation, 
and year 1 IMT, a statistically significant difference in the mean 
progression of the common carotid artery IMT was observed: 
0.032 mm in the intensive treatment group compared to 
0.046 mm in the conventional therapy groups.21
A  second  report  from  EDIC  further  examined 
cardiovascular disease after an average of 17 years of follow 
up. In that assessment, 46 cardiovascular disease events 
occurred in 31 patients in the DCCT intensive treatment 
group compared to 98 events in 52 patients in the conven-
tional group, representing a 42% reduction in any cardio-
vascular event. The risk of nonfatal myocardial infarction, 
stroke, or death from cardiovascular disease was reduced 
by 57% with intensive treatment.22 These data from EDIC 
support the argument that early implementation of intensive 
therapy reduces future incidence of cardiovascular disease. 
Because there was no difference in glycemia as measured 
by HbA1c at the end of the study, these findings support the 
notion that long-lasting and fundamental vascular changes 
can occur early in the course of an illness as a result of 
hyperglycemia. This observation has been described as the 
“imprinting” theory of glycemic control.
Additional studies have supported the findings from 
EDIC. The Wisconsin Epidemiologic Study of Diabetic 
Retinopathy (WESDR) examined a cohort of 879 individuals 
with T1DM free of cardiovascular disease and end-stage 
renal disease at baseline. At the end of 20 years, elevated 
HbA1c was associated with both all-cause and cardiovas-
cular mortality independent of the duration of diabetes, 
smoking, hypertension, and proteinuria.23 A meta-analysis 
of 3 T1DM and 10 T2DM observational studies suggested 
chronic hyperglycemia was associated with an increased risk 
for cardiovascular disease.24 In the prospective Pittsburgh 
Epidemiology of Diabetes Complications study (PEDC), 
glycemia was noted to be a powerful predictor of symptom-
atic lower extremity arterial disease.25
Role of non-glycemic factors: when 
hyperglycemia is not the culprit
Although in patients with diabetes it is attractive to postulate 
hyperglycemia as the ultimate cause of pathology, diabetes is 
a multi-factorial process. There have been studies that have 
not substantiated a relationship between hyperglycemia alone 
and some vascular complications. These studies suggest that 
vascular injury can also result from non-glycemic factors. 
In the case of the microvascular complications of diabetes 
such as nephropathy, retinopathy and neuropathy, the major 
non-glycemic factors include hypertension, smoking, and 
obesity. In the pediatric population, puberty may play an 
additional role as a non-modifiable risk factor.6,8,9
In coronary artery disease, the macrovascular compli-
cation most rigorously studied, there is also evidence that 
suggests contributions from non-glycemic risk factors. 
Reports from two prospective T1DM cohort studies, PEDC 
and EURODIAB, suggested that hyperglycemia was not an Vascular Health and Risk Management 2009:5 1020
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independent predictor of coronary artery disease.26–28 The 
Freemantle Diabetes Study found no link between glycemic 
control and cerebrovascular events in T1DM.29 In 1995, 
a DCCT Research Group report compared the number of 
macrovascular events between T1DM patients treated with 
intensive insulin therapy versus conventional therapy. While a 
42% reduction in macrovascular complications with intensive 
treatment was observed at the study’s completion, it did not 
achieve statistical significance, likely due to the patients’ 
young age at baseline and the exclusion of those with risk 
factors for macrovascular disease at baseline.30 In macro-
vascular disease, hypertension, smoking, obesity, puberty, 
and dyslipidemia all play roles as modifiable non-glycemic 
risk factors.
Hypertension
Persistently elevated blood pressures in patients with diabetes 
can have severe complications on both the micro- and macro-
vascular level. Patients with T2DM often have several risk 
factors for elevated blood pressures, such as obesity, family 
history, and generally poor cardiovascular health. The onset 
of hypertension in T2DM is usually difficult to pinpoint 
due to the uncertainty of disease onset. In patient popula-
tions with T1DM, however, in which onset of disease is 
more certain and there are less confounding alternate risk 
factors, the initiation of, and trend towards, hypertension is 
easier to track.
As the regulation of blood pressure is interconnected to 
the renal system, the onset of renal pathology seen in diabetes 
is usually noted around the time when blood pressure eleva-
tions begin. In diabetic nephropathy, patients will initially 
develop microalbuminuria. Gross proteinuria follows and is 
an indication of widespread microvascular disease. As this 
glomerular damage occurs, patients develop trends of 
elevated blood pressures.
There is some question about when elevated blood 
pressures appear in the progression of diabetic nephropathy – 
whether microalbuminuria precedes it, occurs concurrently, 
or is a secondary effect. Patients with T2DM usually 
have some degree of hypertension at presentation with 
microalbuminuria.31 It is generally noted that patients with 
T1DM have normal in-office blood pressure readings until 
microalbuminuria is detected. This experience leads to the 
general conclusion that microalbuminuria precedes hyper-
tension. However, it has also been shown that increases in 
systolic blood pressure during sleep can precede the onset of 
microalbuminuria in patients with T1DM,31 raising questions 
about the actual mechanism of cause and effect that will need 
to be further elucidated. Once evidence of hypertension and 
nephropathy are both present in patients with diabetes, these 
patients are ultimately at risk of developing renal failure 
and end stage renal disease.32
Hypertension also plays a key role in the pathology of 
diabetic retinopathy. The UKPDS Group demonstrated that 
in patients with T2DM, blood pressure control could delay 
the progression of retinopathy.33 Testa et al demonstrated that 
patients with T1DM who had blood pressures at the upper 
end of the normal range were likely to have progressive 
retinopathy.34 In another study by Chase et al in patients with 
T1DM, mildly elevated systolic and diastolic blood pressure 
ranges above the 90th percentile but less than 141/90 mmHg 
were correlated with the presence of retinopathy.35
There is evidence that hypertension is an independent 
risk factor that can impact the development of diabetic 
neuropathy. A study of the risk factors for distal symmetrical 
polyneuropathy (DSP) found that hypertension showed the 
greatest impact in the development of DSP for individuals 
with diabetes of long and short duration.36 In the Pittsburgh 
cohort of T1DM, hypertension was associated with a 4-fold 
risk of developing DSP over 6 years, and it was found to be 
the single strongest predictor.37 The EURODIAB prospective 
study also demonstrated systolic blood pressure and other 
cardiac risk factors to be strong predictors of DSP, even after 
adjustment for age, duration of disease, and HbA1c.38–40
Smoking
Smoking data, available in the DVP Wiss database based 
on self-reported smoking habits in patients with diabetes, 
show that more than 5% of 11- to 15-year-old school 
children with T1DM reported smoking, and up to 30% of 
adolescents aged 15 to 20 years smoke.41 In patients with 
diabetes, smoking can lead to increased risk of developing 
microvascular and macrovascular complications. A study by 
Hofer et al further showed that smoking may increase the risk 
of complications from T1DM, as smokers demonstrated a 
significantly higher HbA1c than non-smokers.41 The CARDIA 
study showed a higher risk of abnormal glucose tolerance in 
young adults who smoke and in ex-smokers, as compared to 
persons who had never smoked.42 Chiodera et al found that 
smoking induces abnormal secretion of pituitary and counter-
regulatory hormones.43 Smoking can also lead to endothelial 
dysfunction, pathologic changes in low-density lipoprotein 
(LDL) cholesterol, platelet adherence, and inflammation of 
blood vessels.41
Smokers with T1DM have higher rates of microalbuminuria 
than non-smokers. Adverse effects are seen in retinopathy Vascular Health and Risk Management 2009:5 1021
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due to the reduction of retinal blood flow and retinal oxygen 
delivery. A study by Sinha et al following 100 patients over 
6 years demonstrated that retinopathy was twice as prevalent 
in smokers as non-smokers.44 Smoking has been consis-
tently associated with coronary artery disease21,22,27 and, not 
unexpectedly, a smoking-associated increase of cardiovascular 
risk in childhood T1DM has been reported.41
Dyslipidemia
Multiple studies in the T1DM population have implicated 
dyslipidemia as an independent risk factor for coronary artery 
disease.21,22 However, a PEDC report noted that HDL and 
triglyceride levels lacked predictive power for lower extremity 
arterial disease events.25 EDIC showed that progression of 
carotid IMT was associated with the ratio of LDL cholesterol 
to high-density lipoprotein (HDL) cholesterol;21 higher total 
cholesterol and LDL were independently associated with 
cardiovascular disease.22 Jarvisalo et al found that while 
having T1DM is an independent risk factor for increased 
carotid IMT in children, independent correlates for IMT 
also included LDL cholesterol and elevated systolic blood 
pressure.16
In one observational study of patients younger than 
age 21, 15.4% of patients with T1DM had total cholesterol 
(TC) levels greater than 200 mg/dL compared to 11.2% of 
age-matched control subjects from the National Health and 
Nutrition Examination Survey 2001–2002.45 The study also 
found a significant relationship between HbA1c and TC as 
well as HbA1c and non-HDL cholesterol, suggesting poor 
glucose control is often associated with dyslipidemia.
Obesity
It is well understood that obesity in children can have 
metabolic complications including insulin resistance and a 
general risk factor for developing T2DM.46 Even in the T1DM 
population, despite initial weight loss, obesity is becoming 
more prevalent.47 As obesity is associated with hyperten-
sion and dyslipidemia, a patient’s poor nutritional status can 
exacerbate the risk of developing vascular complications of 
diabetes.48 Body mass index has been independently related 
to the development of cardiovascular disease.22
Puberty
There is evidence that puberty itself may be a risk factor for 
the development of vascular complications. This conclusion 
is based on the observations that despite disease duration, 
the majority of the complications initially present or become 
more significant after the onset of puberty.
Puberty is associated with worsening microalbuminuria 
and progression of diabetic nephropathy. Microalbuminuria 
is rare before puberty. An extended pre-pubertal duration 
appears to prolong the time to development of microalbu-
minuria. However, the pre-pubertal duration of diabetes can 
be counted as a contributing factor for microalbuminuria 
after the onset of puberty. Pubertal factors are thought to 
accelerate the development and progression of microalbu-
minuria. These factors include worsening of compliance with 
treatment during adolescence, increases in blood pressure, 
and production of sex steroids influencing the effects of 
hyperglycemia. There are very likely many other unidenti-
fied pubertal factors that contribute to the effects on diabetic 
nephropathy.6
Within the first decade of life, children are at minimal 
risk for retinopathy and ocular complications from diabetes.8 
A study by Rogers et al of diabetic retinopathy in children 
demonstrated that despite similar HbAlc and duration 
of disease, pre-pubertal patients had a lower degree of 
retinopathy than patients in late puberty.49 Klein et al followed 
996 patients with T1DM diagnosed before age 30.50 The 
study was able to identify only one patient between ages 10 to 
14 who had evidence of moderate retinopathy, and just one 
patient under age 10 who had evidence of mild retinopathy. 
Additionally, none of the patients at those ages had retinopathy 
to a degree that would have required any treatment.
Like other microvascular complications of diabetes, 
symptomatic diabetic polyneuropathy is rarely seen in 
young children, with increased signs and symptoms during 
adolescence. A study of puberty and diabetic nephropathy by 
Riihimaa et al evaluated peripheral nerve function in 100 pre- 
and post-pubertal children with T1DM (age 9 years and 
diabetes duration 2 years) and age- and sex-matched 
healthy control subjects.51 This study found increasing 
subclinical motor nerve impairment during late puberty 
and after puberty. They concluded that poor metabolic 
control during puberty due to hormonal changes, and likely 
poor motivation, was the leading cause of peripheral nerve 
function deterioration in patients with T1DM.
Microvascular disease as a risk factor
Interestingly, microvascular disease itself conferred an 
independent risk for macrovascular disease. The results of 
the DCCT suggested that reducing microalbuminuria and 
autonomic neuropathy could be beneficial in reducing macro-
vascular disease.30 EDIC demonstrated that microalbuminuria 
predicted progression of IMT and risk of cardiovascular 
disease.21,22 Renal disease has been shown to be a powerful Vascular Health and Risk Management 2009:5 1022
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predictor of coronary artery disease and peripheral vascular 
disease.25,27
Role of genetic factors
Many of the risk factors discussed above may themselves 
be modified by heritable traits in addition to environmental 
influences. As such, the role of genetic factors is receiving 
emerging attention. Identification of susceptibility genes 
may provide greater understanding of the mechanism of 
these events. To date, investigation into genetic determinants 
and susceptibility to diabetic complications has focused 
primarily on diabetic nephropathy and premature coronary 
artery disease.
In diabetic nephropathy, there is a general observation 
that a peak incidence occurs during the second decade of life 
followed by a decline. This observation leads to the postu-
late that there are subsets of individuals who are susceptible 
to the development of nephropathy during that period as 
compared to those who never go on to develop nephropathy. 
Studies of sibling pairs have shown familial aggregation of 
diabetic nephropathy, where there is an occurrence in more 
members of a family than can be readily accounted for by 
chance. This association provides presumptive evidence of 
the operation of genetic factors. A cohort study by Quinn et al 
found that the cumulative risk of diabetic nephropathy after 
30 years of diabetes was 71.5% in siblings of index cases with 
nephropathy as compared to 25.4% in siblings of index cases 
without nephropathy.52 Parent-offspring pairs and extended 
family studies have also been able to detect similar familial 
aggregation of diabetic nephropathy.53,54
There have also been family studies that show increased 
risk of premature coronary artery disease in family members 
of patients with diabetes who develop these complications. 
It is well established that first-degree relatives of individuals 
with coronary artery disease have an increased risk of 
death themselves from coronary artery disease. A study 
by Wagenknecht et al evaluated how the role of genetic 
factors contributed to atherosclerosis by measuring coronary 
artery calcification and evaluating the extent of familial 
aggregation.55 The study, which involved 122 individuals 
with T2DM (mean age 60 years) and 13 individuals with-
out diabetes in 56 families, found that there were strong 
independent genetic factors that contributed to the variance 
of coronary artery calcification in T2DM.
Genome-wide linkage studies from affected or discordant 
sibling pairs have helped to identify some of the genes 
thought to be involved in increased susceptibility to diabetic 
nephropathy and premature coronary artery disease. Genes 
that are of particular interest include genes involved in the 
glucose-induced pathway such as paraxonase, an enzyme 
involved in detoxification of oxidation end products, and 
aldose reductase, an enzyme involved in the polyol pathway. 
Genes involved in the regulation of renal hemodynamics and 
in the reactivity of vascular cells such as endothelial nitric 
oxide synthase, and genes involved in lipid abnormalities 
such as ApoE are also under investigation. Based on data from 
linkage studies, the genes involved in diabetic nephropathy 
may be detected on chromosomes 3q, 7q, 9q, and 20p.56 
For coronary artery disease, the genes of interest may be on 
2q, 3q, and Xq.57 Work is being done to pinpoint the exact 
locations in these genes where modifications could be made 
to affect variance.
Mechanism of vascular disease
In addition to the clinical data identifying risk factors for 
vascular disease, there are also mechanistic data aimed at 
understanding how these risk factors can be translated at the 
cellular and molecular level into disease progression. These 
studies help to identify those risk factors that may play a 
direct role in vascular disease and also identify a number of 
targets that may be used to modify disease progression.
While the exact mechanism of micro- and macro-vascular 
damage is unclear, at least 3 distinct hyperglycemia-induced 
metabolic pathways appear to be involved in the pathogenesis 
of vascular complications: formation of advanced glycation 
end products (AGEs), activation of protein kinase C (PKC), 
and intracellular hyperglycemia creating disturbances in 
the polyol pathways. These pathways may provide areas of 
possible future medical intervention. In addition to the role 
of glucose metabolism, the renin-angiotensin system and 
the chronic inflammation that characterizes both T1DM 
and T2DM may also play a crucial role in vascular injury. 
An overview of these mechanisms is presented in Figure 2. 
Although an understanding of the mechanism of diabetes 
complications is valuable in appreciating approaches to 
diagnosis and intervention, several excellent reviews have 
considered the pathogenesis of diabetes complications and 
therefore we will not review them further here.58
Screening
Since the micro- and macrovascular complications of 
diabetes may readily become irreversible, it is critical for 
practitioners to detect these changes in patients at a stage 
where early interventions can minimize end-organ damage. 
Good screening tools should be sensitive and reproducible 
in a variety of circumstances. Practitioners should have the Vascular Health and Risk Management 2009:5 1023
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ability to target these screens to most high-risk individuals, 
when the consequence of missing the disease outweighs the 
cost and risk of intervention. Since many of the complications 
of diabetes develop several years after the onset of disease 
in the pediatric population, parameters defining age and 
circumstances to initiate screening are important to establish 
(summarized in Tables 1 to 5).
Nephropathy
Screening for nephropathy includes checking for microal-
buminuria and proteinuria (Table 1). With microalbumin-
uria, patients lose between 30 and 300 mg of albumin in 
24 hours. The threshold of gross proteinuria is reached when 
patients lose over 300mg of albumin in 24 hours. Protein 
loss is greater than 500 mg microalbuminuria per 24 hours 
in diabetic nephropathy. Spot urine proteins can also be 
measured. Early detection of protein loss can help physicians 
monitor a patient’s progression to severe renal disease. 
In adults, nephropathy screening is performed annually in 
T2DM starting at presentation; in T1DM, screening begins 
5 years after onset of disease.59,60 In children with T1DM, 
screening depends upon whether the onset of diabetes is pre- 
or post-pubertal. Patients with pre-pubertal onset of diabetes 
should have screening 5 years after diabetes onset but not 
before age 9 years. In patients with pubertal/post-pubertal 
onset of diabetes, screening for nephropathy is initiated 
2 years after diagnosis, and then performed annually.6 As with 
adult patients, where the onset of T2DM is more insidious, 
screening begins once diagnosed and annually thereafter.
Retinopathy
The development of retinopathy is strongly dependent upon 
the duration of diabetes. It is important that patients with 
diabetes have annual visits to an ophthalmologist to monitor 
for the progression of retinopathy, in order to prevent any 
irreversible vision loss (Table 2). The screening involves the 
assessment of visual acuity and a dilated eye exam to detect 
vascular changes in the retina. Pediatric patients with T1DM 
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should begin screening 3 to 5 years after their diagnosis once 
they have turned 9 years of age according to the American 
Academy of Pediatrics (10 years of age per the American 
Academy of Ophthalmology).20 Since the risk of diabetic 
retinopathy is so small in patients under 9 years of age, they 
generally do not require prior screening regardless of the 
age of onset. Guidelines for pediatric patients with T2DM 
are less clearly defined but generally screening starts once 
diagnosed, as in adult populations.59,60
Neuropathy
Screening for diabetic neuropathy includes checking for 
diminished sensory function and resultant injury (Table 3). 
These screens are performed with routine foot exams to 
evaluate for abrasions, ulcerations, and any evidence of 
Charcot arthropathy. To detect subclinical neuropathies 
and help track the progression of neuropathy, tools like the 
Semmes-Weinstein 10-g monofilament test are used to detect 
decreased pressure sensation to the feet. Tuning forks can 
be used to detect diminished vibratory sensation in the feet. 
Nerve conduction velocities measure the speed of a signal 
through a patient’s nerves based on the degree of myelination 
and are considered the gold standard in testing for peripheral 
neuropathies. This modality is not as readily available in 
most outpatient clinical settings as the non-invasive tests, 
however. A study by Nelson et al raised concerns about the 
sensitivity of non-invasive screens in pediatric patients.61 The 
study examined 73 pediatric patients with T1DM with a mean 
age of 13 and duration of diabetes of at least 5 years. While 
subclinical evidence of diabetic neuropathy was detected 
in 42 (57%) of these patients using nerve conductions 
studies, just 37 (50%) were detected by vibration perception, 
Table 1 Screening for nephropathy in pediatric diabetes
Screening tool 24-hour urine microalbumin
Spot urine microalbumin
Albumin/creatinine ratio in first morning void
Timed overnight urine collection of albumin
Screening parameters Microalbuminuria 24-hour urine sample, spot urine, or first 
morning void:  
30–300 mg albumin/L
Timed overnight urine collection:
20–200 µg/min albumin
Albumin/creatinine ratio in spot urine:
2.5–25 mg/mmol (males)
3.5–25 mg/mmol (females)
Persistent/permanent microalbuminuria Meets above definitions for microalbuminuria 
in a minimum of 2 out of 3 samples collected 
consecutively (preferably within a 3- to 
6-month period)
Gross proteinuria 24-hour albumin loss 500 mg
Age to initiate screening Type 1 diabetes mellitus if diabetes is diagnosed before puberty:
if diabetes is diagnosed before age 4, begin 
screening at age 9
if diabetes is diagnosed between age 6–9, 
begin screening at age 11
if diabetes is diagnosed after age 10, begin 
screening 2 years after diagnosis
if diabetes is diagnosed after puberty:
initiate screening 2 years after diagnosis
Type 2 diabetes mellitus initiate screening at time of diagnosis
Frequency of screening Screening is initially done in 6- 12-month 
intervals
with evidence of intermittent 
microalbuminuria: Repeat testing is done 
every month for the next 3 months 
to confirm the presence of persistent 
microalbuminuria
with evidence of initial microalbuminuria:
Repeat testing is done over the next 
3–6 months to confirm or exclude 
persistent microalbuminuriaVascular Health and Risk Management 2009:5 1025
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26 (35%) were picked up by neurological exam and 19 (26%) 
by tactile perception. Additionally, it was difficult to get full 
cooperation from very young children on the examinations 
that required feedback. The study questioned the utility of 
non-invasive testing in the pediatric population as a proper 
screening modality when compared with the gold standard 
of nerve conduction studies.
Hypertension
Because hypertension confers increased risk for the onset 
of microvascular complications and macrovascular com-
plications later in adulthood, blood pressure monitoring 
and management is a key component of  pediatric diabetes 
management (Table 4). Hypertension is defined in pedi-
atric patients as an average systolic or diastolic blood 
pressure 95th percentile for age, sex, and height mea-
sured on 3 separate days; or a high-normal blood pressure 
with average systolic or diastolic blood pressure 90th 
but 95th percentile for age, sex, and height measured on 
3 separate days.62 Blood pressure should be assessed rou-
tinely at each clinical visit with other standard vital signs to 
monitor trends and detect elevations at an early stage. Obtain-
ing 24-hour ambulatory blood pressure measurements can 
be useful in managing patients with persistently high clinical 
blood pressures before and after initiating antihypertensives.6 
Discussing the family history of diabetes, hypertension, and 
the prevalent complications in a family can also provide 
clues to practitioners to guide decisions about management 
and interventions.
Hyperlipidemia
Dyslipidemia is also a critical but modifiable factor that 
should be considered in preventing or minimizing macro-
vascular disease. Although it is rare to see overt signs of 
atherosclerosis in pediatric patients with T1DM, the findings 
of EDIC, as mentioned above, highlight the importance of 
Table 2 Screening for retinopathy in pediatric diabetes
Screening tool Visual acuity exam Asses ability to focus and discern objects
Dilated eye exam Detects vascular changes in the retina
Fundus photography and angiography Quantifies degree of retinopathy
Screening parameters evidence of background nonproliferative 
retinopathy
Findings: Microaneurysms, dot and blot 
hemorrhages, hard exudates
evidence of preproliferative retinopathy 
and retinal ischemia
Findings: cotton wool spots
evidence of proliferative retinopathy with Findings: neovascularization of the optic disk
Age to initiate screening Type 1 diabetes mellitus Starting at age 9, screen 3–5 years after 
diagnosis
Type 2 diabetes mellitus Starting at age 9, screen at time of diagnosis
Frequency of screening Type 1 diabetes mellitus: annually Type 2 diabetes mellitus: annually
Table 3 Screening for neuropathy in pediatric diabetes
Screening tool Nerve conduction velocities The gold standard: determines the adequacy 
of impulse the conduction of through nerves
Semmes-Weinstein monofilament test Detects pressure perception
Tuning forks Detects vibration perception
Survey of symptoms Review of systems to detect new symptoms 
such as numbness, pain, cramps, paresthesias, 
alteration of sensation in vibration and light 
touch
Cardiovascular autonomic function 
testing
Detects reduced heart rate variability
Screening parameters All modalities screen for evidence of loss of sensitivity and non-perception
Age to initiate screening Type 1 diabetes mellitus Starting after 5 years of disease
Type 2 diabetes mellitus Starting at the time of diagnosis
Frequency of screening Type 1 diabetes mellitus: annually Type 2 diabetes mellitus: annuallyVascular Health and Risk Management 2009:5 1026
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preventative screening for future vascular complications in 
these children (Table 5).
Because of the increased risk conferred by both dyslip-
idemia and hyperglycemia for atherosclerosis, the American 
Diabetes Association (ADA) recommends cholesterol 
screening.62 For pre-pubertal children, a fasting lipid profile 
should be obtained on all children older than 2 years of 
age at the time of diagnosis and glucose control has been 
established, if there is a family history of hypercholes-
terolemia, if there is a family history of a cardiovascular 
event before age 55, or if such a family history is unknown. 
If family history is not of concern, lipid screening should 
occur at puberty. If a child is diagnosed after puberty, lipids 
should be checked at time of diagnosis. In the case of both 
age groups, if LDL is  100 mg/dL, a lipid profile should 
be obtained every 5 years. Borderline or abnormal values 
should be repeated for confirmation.
Preventative therapy and treatment
Along with screening, preventative therapy guidelines can 
help mitigate the risks of developing vascular complications. 
When evidence of end-organ damage becomes detectable 
as a result of screening, interventions can be initiated in an 
attempt to halt further progression of disease and salvage 
organ function. Because of common risk factors shared 
by the micro- and macro-vascular complications, many 
of the initial interventions will have beneficial effects on 
several developing complications. When end-organ dam-
age does occur, therapies become directed to preserve the 
affected organ.
Table 4 Screening for hypertension in pediatric diabetes
Screening tool In-office blood pressure Static measurement of sphygmomanometer cuff 
pressure
24-hour ambulatory blood pressure Measures blood pressure at regular intervals 
throughout the day
Screening parameters High-normal blood pressure Findings: average systolic or diastolic blood pressure 
90th but 95th percentile for age, sex, and 
height measured on three separate days
Hypertension Findings: average systolic or diastolic blood pressure 
95th percentile for age, sex, and height measured 
on three separate days
Age to initiate screening Type 1 diabetes mellitus Starting at time of diagnosis
Type 2 diabetes mellitus Starting at time of diagnosis
Frequency of screening Type 1 diabetes mellitus: every office visit Type 2 diabetes mellitus: every office visit
Table 5 Screening for dyslipidemia in pediatric diabetes
Screening tool Fasting lipid profile:
LDL, HDL, triglycerides
Determines the body’s utilization and storage 
of lipids
Screening parameters LDL cholesterol Target: goal level  110 mg/dL
HDL cholesterol Target: goal level  35 mg/dL
Triglycerides Target: goal level  150 mg/dL
Total cholesterol Target: goal level  170 mg/dL
Age to initiate screening Type 1 diabetes mellitus if diabetes is diagnosed before puberty:
with risk factors for dyslipidemia: initiate 
screening in all children over 2 years of age
with no risk factors for dyslipidemia: initiate 
screening in all children at 12 years of age
if diabetes is diagnosed after puberty:
initiate screening at time of diagnosis
Type 2 diabetes mellitus initiate screening at time of diagnosis
Frequency of screening  if lipids are normal: screen every 2–5 years 
in type 1 and type 2 diabetes mellitus
if lipids are abnormal: screen annually in type 1 
and type 2 diabetes mellitus
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.Vascular Health and Risk Management 2009:5 1027
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Glucose management
With hyperglycemia as a key culprit in the micro- and 
macro-vascular complications of diabetes, a primary pre-
ventative intervention is maintaining euglycemia. This goal 
is best achieved with intensive glycemic control, which 
includes blood glucose monitoring throughout the day, and 
appropriate treatment with insulin in T1DM and the addi-
tion of other blood glucose lowering medications in T2DM. 
In the DCCT, intensive therapy for glycemic control was 
associated with excess weight gain and increased risk of 
hypoglycemia. Hypoglycemia is a predictable but concerning 
complication of intensive glycemic control. Compared to the 
conventional therapy group, study patients had up to a 3-fold 
greater risk of hypoglycemia with severe consequences such 
as seizures and loss of consciousness.1 To minimize the risk 
for hypoglycemia, recommendations in pediatric patients 
are to maintain HbA1c within the range of 7.5% to 8.5%, 
depending upon age.62
Encouraging appropriate record keeping of blood glucose 
levels and insulin administration will also help physicians 
make fine adjustments in patients’ insulin regimens as they 
grow. Logbooks are more prone to user error, however, 
as patients may inaccurately input data or fail to record their 
data. Laffel et al demonstrate that the use of meters with 
electronic logbooks can be associated with improvement of 
glycemic control as compared to paper logbooks, in both 
adult and pediatric populations.63 New innovations such as 
closed-loop blood glucose monitoring and insulin delivery 
may help patients maintain appropriate glucose levels to 
avoid the consequences of hypoglycemia or hyperglycemia 
and the resultant vascular complications. In addition to the 
hyperglycemic risk factors, some non-glycemic risk factors 
such as smoking, weight management, dyslipidemia, and 
hypertension also provide areas to target preventative therapy 
and treatment.
Smoking
As discussed previously, smoking has been shown to 
exacerbate micro- and macro-vascular complications in 
diabetes.6 Smoking generally begins in the teenage years. 
It has been demonstrated that pediatric practice-based 
smoking cessation and prevention intervention methods 
have been effective in deterring smoking in adolescents.64
weight management
Moderate weight loss in overweight adolescents has been 
shown to increase insulin sensitivity in the liver and skeletal 
muscles and improve glycemic control.46 Anticipatory guidance, 
as well as nutrition and exercise counseling by pediatric 
providers, can help families make healthy decisions to pre-
vent obesity and its complications.
Dyslipidemia
Prevention of dyslipidemia aims to protect diabetic patients 
from atherosclerotic disease. Initial prevention for dyslip-
idemia should focus on optimizing blood glucose control, 
decreasing total and saturated fat intake, controlling 
weight, and cessation of smoking if applicable. The addi-
tion of lipid-lowering agents is recommended in pediatric 
patients if LDL  160 and for patients with LDL of 130 to 
159 if lifestyle and dietary interventions fail to achieve 
a goal LDL  100 mg/dL. The ADA position statement 
suggests the use of HMG-CoA reductase inhibitors, which 
have been approved for children older than 10 years of 
age and have been shown to be both safe and efficacious 
in early trials with children with heterozygous familial 
hypercholesterolemia and T1DM.65,66 The 2008 American 
Academy of Pediatrics policy statement on cholesterol in 
childhood recommends treating children with hypercho-
lesterolemia under age 8 years only in the most extreme 
circumstances (LDL  500 mg/dL).67 For this reason, the 
onset of puberty is a reasonable time to begin lipid lowering 
agents in most cases.
Hypertension
The prevention and management of hypertension may have 
the broadest effect on both micro- and macro-vascular 
complications. To manage hypertension in pediatric 
patients with diabetes, angiotensin converting enzyme 
(ACE) inhibitors, which have been shown to have ben-
eficial microvascular protective effects, are first-line 
drugs of choice. Once persistent hypertension has been 
established by the appropriate screening modalities, non-
diabetes related causes of hypertension should be excluded. 
Hypertension is then initially managed with increased 
exercise and a low- to salt-free diet. If blood pressure has 
not been reduced to 90th percentile or 130/80 mmHg 
within 3 to 6 months of lifestyle intervention, pharmaco-
logic therapy should be initiated. ACE inhibitors should 
be considered. This class of medication has been shown to 
be efficacious and safe in children from age 6 to 16 years 
and is FDA-approved for ages 6 years and older.68,69 ACE 
inhibitors are contraindicated in pregnancy. In addition 
to the benefit of reducing hypertension, ACE inhibitors 
confer benefit by reducing macrovascular disease, indepen-
dent of blood pressure reduction in adults with T1DM,70 Vascular Health and Risk Management 2009:5 1028
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may improve endothelial dysfunction associated with 
atherosclerosis,71 and may also reduce oxidative stress on 
the endothelium.72
Despite the wide range of potential benefits of ACE-
inhibitors, their therapeutic potential has been most 
strongly associated with prevention of renal microvascu-
lar complications. Their efficacy in this setting has been 
the focus of numerous clinical studies. In the Patients 
with Type 2 Diabetes and Microalbuminuria study which 
evaluated irbesartan, an angiotensin receptor blocker (ARB), 
urine albumin excretion was decreased by 38% and the 
risk of microalbuminuria was reduced by 70% compared 
to placebo.73 The Heart Outcomes Prevention Evaluation 
(HOPE) study demonstrated that in patients with diabetes, 
ACE inhibitors could decrease the progression to overt 
nephropathy by 24% compared to placebo at similar blood 
pressures.70 It is thought that by blocking the trophic effects 
of angiotensin II, these drugs help minimize the glomerular 
hypertrophy and mesangial matrix damage that occurs in 
the kidney as a result of long-term stimulation of the renin 
angiotensin system.
Adult patients are generally started on these antihyper-
tensive medications with evidence of microalbuminuria. 
There is controversy about when to begin pediatric patients 
on these antihypertensive regimens, as these patients can 
have transient microalbuminuria during puberty that resolves 
afterwards.44 Starting all pediatric patients with evidence of 
microalbuminuria on drug therapy could lead to prolonged 
and unnecessary treatment. Delaying treatment, however, 
could result in preventable kidney damage.
While blockade of the renin–angiotensin system with 
ACE inhibitors and ARBs has been shown to slow the 
progression of nephropathy in diabetic patients with pro-
teinuria and reduced glomerular filtration rate, a recent 
study by Mauer et al, the Renin-Angiotensin System Study 
(RASS), challenges the efficacy of ACE inhibitors and 
ARBs in slowing the early histologic changes of diabetic 
nephropathy in normotensive patients before albuminuria is 
present.74 The study evaluated enalapril and losartan against 
placebo to detect changes in mesangial fractional volume 
per glomerulus over a 5-year period in patients with T1DM. 
They found that the change in mesangial fractional volume 
did not differ significantly between ACE inhibitors, ARBs, 
or placebo. Furthermore the 5-year cumulative incidence 
of microalbuminuria was found to be higher in patients on 
losartan than enalapril and placebo. These new data raise 
questions about the utility of ACE inhibitors and ARBs in 
early asymptomatic stages of TIDM.
Although the RASS study raises questions about the 
efficacy of ACE inhibitors and ARBs in pre-symptomatic 
nephropathy, their use was correlated with a significant 
reduction in the progression of retinopathy when compared 
with placebo in patients with T1DM.74 When compared with 
placebo, progression of retinopathy was reduced by 65% 
with the ACE inhibitor enalapril and 70% with the ARB 
losartan. These data suggest that despite unproven efficacy 
in preventing the progression of nephropathy in asymptom-
atic patients, ACE inhibitor and ARBs could still serve an 
important role in the prevention of retinopathy.
Presently, there is no official consensus about the 
initiation of drug treatment with ACE inhibitors and ARBs in 
the pediatric population with diabetes. Based on available 
information and risk factors, Chiarelli et al suggest treat-
ment should be directed at pediatric patients in puberty with 
persistent microalbuminuria and hypertension, and in patients 
with microalbuminuria and additional signs of microvascular 
complications such as retinopathy.75 Pubertal pediatric 
patients with persistent microalbuminuria but normal blood 
pressures may be started on a trial of ACE inhibitors if 
modifications such as blood glucose control, reduction of 
protein intake, and smoking cessation have not improved 
the microalbuminuria. Reassessment after puberty would be 
warranted to avoid unnecessary prolonged treatment, as the 
microalbuminuria may resolve.
Summary
The macro- and microvascular complications of diabetes 
are driven by both glycemic and non-glycemic factors. The 
available evidence suggests that optimal control of blood 
sugar will significantly modify the risk for these factors, 
but even optimal glucose control may not be protective in 
all cases. Thus, the approach to prevention of the complica-
tions of diabetes requires a more holistic approach to body 
metabolism.
However, in considering the application of multiple 
pharmacologic approaches in the adolescent, we must also 
consider the impact on the young person with diabetes and 
his or her family. Indeed, those patients in whom we are 
most likely to recommend additional interventions to prevent 
complications are those that may already be struggling 
substantially with diabetes care. Adolescence, in particular, is 
a time when compliance with medications may be lower than 
at any other time in life.76 Thus, there may be greater risk in 
these patients for chronic hyperglycemia, dyslipidemia, and 
the progression of complications. Although it has not been 
well-studied in children, adherence with even basic diabetes Vascular Health and Risk Management 2009:5 1029
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regimens is a well-described challenge.77 As the regimens 
increase in complexity (more drugs, more times per day), 
adherence invariably drops.78 The introduction of additional 
pharmacotherapies may detract from the principle use of 
insulin or oral hypoglycemics and exacerbate hyperglycemia 
and risk for complications.
In addition to the challenges posed to adherence by 
additional medicines, older patients have also articulated 
that they feel like “failures” when they are prescribed an 
additional medication for a new problem, even if the new 
problem is not unexpected.79 Adolescents, even without 
chronic illness, may struggle with self-esteem; care must be 
taken by providers to help patients understand the need for 
additional medicines and the role of the patient on the medical 
team and in the treatment of their illness. Finally, these 
issues may also be compounded by undiagnosed depression, 
which further limits medication adherence.80–83 Depression 
in adolescents can be difficult to diagnose, particularly for 
the busy practitioner in an office setting that is not optimized 
for this screening. Nonetheless, although prescribed medical 
therapy can be optimized to prevent complications by the 
mechanisms described above, the delivery of these medicines 
to the patients is likely to remain a substantial challenge.
Our understanding of diabetes, its complications, and 
their risk factors has expanded substantially in the last 
15 years. There are exciting new agents with which to opti-
mize glycemic control and new targets to reduce glucose 
variability including insulin analogs, insulin pump therapy, 
and the promise of closed-loop insulin delivery. However, 
our emerging understanding suggests that even optimal glu-
cose control may not minimize risk in all patients and that 
other pathways may require targeting as well. The clinical 
approach to diabetes is likely to continue to integrate these 
new findings with ever tighter goals for biochemical and 
physical parameters. For many of our patients, particularly 
those with T1DM but also those with T2DM, the diabetes 
diagnosis will be made in childhood and early adolescence. 
Prevention of complications should begin simultaneously, 
targeting initially optimal glucose control but expanding as 
needed to address these other parameters. As these goals 
are better understood and integrated into adult and pediatric 
practice, we hope practitioners will be able to provide a con-
sistent message about treatment goals and methods across 
the lifetime of each individual with diabetes that may further 
improve adherence to these complex regimens.
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